Bracco Diagnostics
As of the edition of 20 October 2026, Bracco Diagnostics runs 33 drugs, 32 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 32 |
| Stopped | 1 |
| Total | 33 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyanocobalamin | none listed | 0 |
| Sulfur hexafluoride | none listed | 0 |
| Gadobenate dimeglumine | none listed | 0 |
| Iopamidol | Ends 2028 (exclusivity) | 0 |
| Sodium phosphate, dibasic, anhydrous | none listed | 0 |
| Gadoteridol | none listed | 0 |
| Diatrizoic acid | none listed | 0 |
| Selenomethionine | none listed | 0 |
| Technetium tc 99m sulfur colloid | none listed | 0 |
| Manganese chloride anhydrous | none listed | 0 |
| Rose bengal free acid | none listed | 0 |
| Sincalide | none listed | 1 |
| Sodium iodide | none listed | 0 |
| Barium | none listed | 0 |
| Iodohippurate | none listed | 0 |
| Iomeprol | Ends 2029 (exclusivity) | 0 |
| Rubidium chloride | none listed | 0 |
| Sodium chromate | none listed | 0 |
| Sodium pertechnetate | none listed | 0 |
| Technetium tc 99m albumin aggregated | Ended 1988 (computed from the first US licence) | 0 |
| Technetium mebrofenin | none listed | 0 |
| Thallous chloride | none listed | 0 |
| Barium sulfate | none listed | 0 |
| Chlormerodrin | none listed | 0 |
| Iodamide | none listed | 0 |
A route B row is one company at one target. 7 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| KDR Vascular endothelial growth factor receptor 2 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Bracco Diagnostics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 4 trials led
- Urinary and reproductive: 4 trials led
- Hormones: 2 trials led